Cargando…

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection

An 81-year-old woman developed liver dysfunction after two months' treatment with direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection. She was positive for serum anti-nuclear antibody, with an elevated immunoglobulin G level. A liver biopsy revealed high-grade interfac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Kotaro, Kikuchi, Kentaro, Kajiyama, Yusuke, Takano, Yuichi, Mabuchi, Masatoshi, Doi, Shinpei, Sato, Koichiro, Miyakawa, Hiroshi, Yasuda, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191578/ https://www.ncbi.nlm.nih.gov/pubmed/29709942 http://dx.doi.org/10.2169/internalmedicine.0613-17

Ejemplares similares

Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin
por: Kuniyoshi, Noriyuki, et al.
Publicado: (2019)

Immunoglobulin G4-related Liver Disease Overlapping with Non-alcoholic Steatohepatitis That Was Diagnosed Simultaneously with Autoimmune Pancreatitis: A Case Report and Review of the Literature
por: Matsumoto, Kotaro, et al.
Publicado: (2019)

B-Cell-Activating Factor Affects the Occurrence of Thyroid Autoimmunity in Chronic Hepatitis C Patients Treated with Interferon Alpha
por: Kajiyama, Yusuke, et al.
Publicado: (2012)

Retrograde pancreatic stent extrusion through the EUS-guided pancreaticogastrostomy route
por: Doi, Shinpei, et al.
Publicado: (2017)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Peroral Cholangioscopy-Guided Targeted Biopsy versus Conventional Endoscopic Transpapillary Forceps Biopsy for Biliary Stricture with Suspected Bile Duct Cancer
por: Sekine, Katsunori, et al.
Publicado: (2022)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
por: Sato, Ken, et al.
Publicado: (2022)

Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma
por: Matsumoto, Kotaro, et al.
Publicado: (2021)

Curative Effects for B-Cell Lymphoma Accomplished by Direct-Acting Antiviral Agents of Hepatitis C
por: Hattori, Nobuhiro, et al.
Publicado: (2017)

Risk factors for liver‐related mortality of patients with hepatitis C virus after sustained virologic response to direct‐acting antiviral agents
por: Hattori, Nobuhiro, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Disseminated Bone Marrow Carcinomatosis Due to Malignant Melanoma of Unknown Primary Origin
por: Matsumoto, Kotaro, et al.
Publicado: (2021)

Fructo-oligosaccharides and intestinal barrier function in a methionine–choline-deficient mouse model of nonalcoholic steatohepatitis
por: Matsumoto, Kotaro, et al.
Publicado: (2017)

Serological and Histological Examination of a Nonalcoholic Steatohepatitis Mouse Model Created via the Administration of Monosodium Glutamate
por: Takai, Atsuko, et al.
Publicado: (2014)

Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience
por: Kaneko, Rena, et al.
Publicado: (2018)

Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis
por: Torisu, Yuichi, et al.
Publicado: (2017)

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C
por: Yamazaki, Tomoo, et al.
Publicado: (2018)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fo3dlrmslqiof4v000lum8tqv5